<DOC>
	<DOCNO>NCT02646072</DOCNO>
	<brief_summary>The purpose study determine whether relationship inflammatory cytokine aqueous eye thickness macula treatment topical ketorolac patient undergo cataract surgery .</brief_summary>
	<brief_title>Effect Preoperative Topical Ketorolac Aqueous Cytokine Levels Macular Thickness Cataract Surgery Patients</brief_title>
	<detailed_description>To compare aqueous level inflammatory cytokine diabetic non diabetic patient treat preoperative topical ketorolac tromethamine 0.45 % . To compare macular thickness change diabetic non diabetic patient treat preoperative ketorolac tromethamine 0.45 % correlation aqueous inflammatory cytokine .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diabetic patient group 1 . Type 2 diabetes mellitus diabetic retinopathy 2 . If comorbid , control hypertension hypertensive crisis recent six month 3 . Listed phacoemulsification cataract surgery Non diabetic patient group 1 . No history diabetes 2 . If comorbid , control hypertension hypertensive crisis recent six month 3 . Listed phacoemulsification cataract surgery 1 . Smoker 2 . Presence immune disease , local systemic inflammation 3 . Presence retinal disease , glaucoma 4 . Previous surgical procedure eye 5 . Intraoperative complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>aqueous humor</keyword>
	<keyword>inflammatory cytokine</keyword>
	<keyword>cystoid macular edema , postoperative</keyword>
	<keyword>nonsteroidal anti-inflammatory drug</keyword>
</DOC>